Glaukos Corp. Reports Strong Q1 2025 Growth

Glaukos Corp. ( (GKOS) ) has released its Q1 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases. In the first quarter of 2025, Glaukos reported record net sales of $106.7 million, marking a 25% increase from the previous year, driven by strong performance in its glaucoma segment.

The company achieved a gross margin of approximately 77% and a non-GAAP gross margin of 82%. Selling, general, and administrative expenses rose by 14% to $70.7 million, while research and development expenses increased by 5% to $32.4 million. Despite these expenses, Glaukos reduced its net loss to $18.1 million, or $0.32 per diluted share, compared to a $40.8 million loss in the same quarter of 2024.

Glaukos’s strategic focus on advancing its pipeline of novel, dropless platform technologies has contributed to its growth. The company’s U.S. glaucoma sales saw a 41% year-over-year increase, reflecting successful execution of its strategic plans. The reaffirmed 2025 net sales guidance of $475 million to $485 million underscores the company’s confidence in its growth trajectory.

Looking ahead, Glaukos remains committed to advancing its innovative therapies and maintaining its growth momentum. The management’s outlook suggests continued focus on executing strategic plans and expanding its market presence in the ophthalmic sector.